341 related articles for article (PubMed ID: 29633898)
21. Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer.
Mohammad HP; Barbash O; Creasy CL
Nat Med; 2019 Mar; 25(3):403-418. PubMed ID: 30842676
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic cancer therapy: Proof of concept and remaining challenges.
Mund C; Lyko F
Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
[TBL] [Abstract][Full Text] [Related]
23. The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry.
Zhao H; Ning S; Nolley R; Scicinski J; Oronsky B; Knox SJ; Peehl DM
Clin Epigenetics; 2017; 9():4. PubMed ID: 28149332
[TBL] [Abstract][Full Text] [Related]
24. Expression and regulation of human endogenous retrovirus W elements.
Li F; Karlsson H
APMIS; 2016; 124(1-2):52-66. PubMed ID: 26818262
[TBL] [Abstract][Full Text] [Related]
25. Vitamin C increases viral mimicry induced by 5-aza-2'-deoxycytidine.
Liu M; Ohtani H; Zhou W; Ørskov AD; Charlet J; Zhang YW; Shen H; Baylin SB; Liang G; Grønbæk K; Jones PA
Proc Natl Acad Sci U S A; 2016 Sep; 113(37):10238-44. PubMed ID: 27573823
[TBL] [Abstract][Full Text] [Related]
26. [Development of novel epigenetic molecular-targeting agents].
Sowa Y; Sakai T
Nihon Rinsho; 2015 Aug; 73(8):1263-7. PubMed ID: 26281676
[TBL] [Abstract][Full Text] [Related]
27. Beyond regulations at DNA levels: A review of epigenetic therapeutics targeting cancer stem cells.
Zhang S; Gong Y; Li C; Yang W; Li L
Cell Prolif; 2021 Feb; 54(2):e12963. PubMed ID: 33314500
[TBL] [Abstract][Full Text] [Related]
28. DNA demethylating agents and histone deacetylase inhibitors in hematologic malignancies.
Fandy TE; Carraway H; Gore SD
Cancer J; 2007; 13(1):40-8. PubMed ID: 17464245
[TBL] [Abstract][Full Text] [Related]
29. Dual targeting of epigenetic therapy in cancer.
Hellebrekers DM; Griffioen AW; van Engeland M
Biochim Biophys Acta; 2007 Jan; 1775(1):76-91. PubMed ID: 16930846
[TBL] [Abstract][Full Text] [Related]
30. Current limitations and future opportunities for epigenetic therapies.
Cherblanc F; Chapman-Rothe N; Brown R; Fuchter MJ
Future Med Chem; 2012 Mar; 4(4):425-46. PubMed ID: 22416773
[TBL] [Abstract][Full Text] [Related]
31. Anticancer activities of histone deacetylase inhibitors.
Bolden JE; Peart MJ; Johnstone RW
Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
[TBL] [Abstract][Full Text] [Related]
32. Systematic identification and characterization of regulatory elements derived from human endogenous retroviruses.
Ito J; Sugimoto R; Nakaoka H; Yamada S; Kimura T; Hayano T; Inoue I
PLoS Genet; 2017 Jul; 13(7):e1006883. PubMed ID: 28700586
[TBL] [Abstract][Full Text] [Related]
33. DNMT inhibitors and HDAC inhibitors regulate E-cadherin and Bcl-2 expression in endometrial carcinoma in vitro and in vivo.
Yi TZ; Li J; Han X; Guo J; Qu Q; Guo L; Sun HD; Tan WH
Chemotherapy; 2012; 58(1):19-29. PubMed ID: 22343305
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic regulation of gene expression as an anticancer drug target.
Ferguson LR; Tatham AL; Lin Z; Denny WA
Curr Cancer Drug Targets; 2011 Feb; 11(2):199-212. PubMed ID: 21158714
[TBL] [Abstract][Full Text] [Related]
35. Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies?
Amin SA; Adhikari N; Jha T
Pharmacol Res; 2017 Aug; 122():8-19. PubMed ID: 28501516
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
37. [Histone deacetylase inhibitors: highlight on epigenetic regulation].
Pécuchet N; Cluzeau T; Thibault C; Mounier N; Vignot S
Bull Cancer; 2010 Aug; 97(8):917-35. PubMed ID: 20483706
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
39. DNA methyltransferases: emerging targets for the discovery of inhibitors as potent anticancer drugs.
Yu J; Xie T; Wang Z; Wang X; Zeng S; Kang Y; Hou T
Drug Discov Today; 2019 Dec; 24(12):2323-2331. PubMed ID: 31494187
[TBL] [Abstract][Full Text] [Related]
40. Histone Deacetylase Inhibitors as Anticancer Drugs.
Eckschlager T; Plch J; Stiborova M; Hrabeta J
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
